mekinist
(trametinib)Novartis Pharmaceuticals Corporation
Usage: MEKINIST is indicated for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, anaplastic thyroid cancer, unresectable solid tumors, and low-grade glioma in pediatric patients, often in combination with dabrafenib. Not indicated for colorectal cancer.